Company Overview
Equillium, Inc., a clinical-stage biotechnology company, develops therapeutics to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders in the United States. The company develops EQ504, a novel AhR modulator that is in preclinical-stage for the treatment of ulcerative colitis and lung inflammation diseases. It also develops EQ302, a bi-specific inhibitor of IL-15 and IL-21 formulated for oral delivery for the treatment of celiac diseases. The company was formerly known as Attenuate Biopharmaceuticals, Inc. and changed its name to Equillium, Inc. in May 2017. Equillium, Inc. was incorporated in 2017 and is headquartered in La Jolla, California.
Why Investors Should Care
Revenue has grown at a 61.5% CAGR over the past five years.
Recent Developments
- Trailing 12 Months Year-on-year growth — revenue +13.9%.
- 5-Year Trend Long-term compounding — revenue CAGR 61.5%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 61.48% |
| 1 Year: | 13.89% |
Stock Price Performance
| 1 Year: | +159.14% |
| 6 Months: | +19.31% |
| 3 Months: | -13.00% |
| 1 Month: | +14.22% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMAAbove
- RSI (14)53.70 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Compounding revenue at 61.5% over 5 years.
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
No notable concerns flagged.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | EQ Equillium, Inc. PHARMA | 2.41 | -26.78 | $152.81M | 0.00% | -81.63% | -58.98% | 61.48% | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,123.91 | 37.80 | $1.00T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 269.12 | 31.22 | $648.55B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 248.78 | 70.48 | $439.62B | 2.78% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 148.46 | 118.77 | $366.28B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 400.84 | 25.74 | $359.79B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 137.70 | 20.80 | $261.73B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 160.04 | 23.99 | $248.20B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 603.02 | 32.49 | $222.97B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Jun 2017 | Sep 2017 | Dec 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Dec 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 8.88M | 9.12M | 8.87M | 10.69M | 13.85M | 12.16M | - | - | - | - |
| Operating Income | - | -83.71K | - | -1.04M | -1.12M | -2.23M | - | -6.35M | -6.44M | -6.32M | - | -7.45M | -6.61M | -6.52M | - | -8.70M | -8.84M | -9.86M | -37.33M | -13.55M | -13.24M | -4.11M | -3.59M | -3.62M | -2.79M | -100.00K | -679.00K | -8.87M | -6.23M | -4.58M | -5.61M |
| Net Income | -947.30K | -141.03K | -1.11M | -1.58M | -1.76M | -4.92M | -4.99M | -5.95M | -6.07M | -6.01M | -7.57M | -7.84M | -6.46M | -6.60M | -8.92M | -8.99M | -9.16M | -10.28M | -37.42M | -14.13M | -13.65M | -3.94M | -3.34M | -3.71M | -2.73M | 468.00K | -7.00K | -8.65M | -5.74M | -4.23M | -5.31M |
| Diluted EPS | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -0.31 | -0.35 | -1.17 | -0.41 | -0.40 | -0.11 | -0.10 | -0.11 | -0.08 | 0.01 | 0.00 | -0.24 | -0.16 | -0.06 | -0.06 |
| R&D Expense | - | 49.95K | - | 663.00K | 540.00K | 1.22M | - | 3.76M | 4.25M | 4.18M | - | 4.71M | 3.89M | 4.22M | - | 5.88M | 5.99M | 6.96M | - | - | - | - | - | - | - | - | - | - | - | - | - |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | 15.76M | 36.08M | 41.09M | - |
| Operating Income | -8.62M | -26.73M | -29.55M | -37.79M | -62.08M | -14.52M | -8.27M | -23.63M |
| Net Income | -13.25M | -25.60M | -29.81M | -39.05M | -62.43M | -13.34M | -8.07M | -22.40M |
| Diluted EPS | - | - | - | -1.36 | -1.85 | -0.38 | -0.23 | -0.39 |
| R&D Expense | 4.94M | 17.64M | 19.38M | 26.38M | 37.55M | 37.04M | - | - |
Balance Sheet (Annual)
Figures in USD.
| Metric | Mar 2017 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | 7.15M | 67.16M | 55.54M | 85.43M | 85.41M | 78.42M | 50.53M | 25.60M | 31.89M |
| Total Equity | 0 | -2.25M | 64.94M | 41.85M | 69.85M | 66.50M | 31.94M | 22.57M | 19.06M | 28.60M |
| Cash & Equivalents | - | 7.10M | 28.51M | 13.22M | 23.98M | 50.37M | 59.11M | 23.22M | 18.09M | 30.28M |
| Long Term Debt | - | - | - | 9.68M | 8.28M | 8.75M | 3.24M | - | - | - |
| Total Liabilities | - | 9.40M | 2.23M | 13.69M | 15.57M | 18.90M | 46.48M | 27.96M | 6.54M | 3.29M |
| Current Liabilities | - | 568.82K | 2.03M | 3.88M | 7.25M | 8.91M | 32.04M | 27.57M | 6.36M | 2.93M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -7.53M | -22.95M | -24.62M | - | -8.73M | -21.78M | -19.03M | -22.75M |
| Investing Cash Flow | -37.43M | -2.17M | -18.59M | - | 18.68M | -4.76M | 13.81M | 4.46M |
| Financing Cash Flow | 66.36M | 9.84M | 53.95M | - | -1.22M | -9.23M | 164.00K | 30.43M |
| Capital Expenditure | -35.00K | -74.00K | -202.00K | - | -279.00K | -50.00K | -85.00K | -48.00K |
| Free Cash Flow | -7.56M | -23.02M | -24.83M | - | -9.01M | -21.83M | -19.11M | -22.79M |
| Net Change in Cash | - | - | - | - | 8.74M | -35.77M | -5.05M | 12.14M |
| Share Buybacks | - | - | - | - | - | 260.00K | - | - |
Ratios (Annual)
Figures in %.
| Metric | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - | - |
| Operating Margin % | - | - | - | - | -393.9% | -40.2% | -20.1% | - |
| Net Margin % | - | - | - | - | -396.1% | -37.0% | -19.6% | - |
| ROE % | -20.4% | -61.2% | -42.7% | -58.7% | -195.4% | -59.1% | -42.3% | -78.3% |
| ROCE % | -13.2% | -51.7% | -37.8% | -49.4% | -133.8% | -63.3% | -43.0% | -81.6% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Jupiter Topco LLC | 10.24% | 6.49M | $12.47M |
| 2 | Decheng Capital LLC | 7.01% | 4.45M | $8.54M |
| 3 | Affinity Asset Advisors, Llc | 6.47% | 4.10M | $7.87M |
| 4 | Adar1 Capital Management, LLC | 5.93% | 3.76M | $7.22M |
| 5 | Aberdeen Group plc | 5.73% | 3.63M | $6.97M |
| 6 | Woodline Partners LP | 5.52% | 3.50M | $6.72M |
| 7 | RA Capital Management, L.P. | 4.88% | 3.10M | $5.94M |
| 8 | Stempoint Capital LP | 3.18% | 2.02M | $3.87M |
| 9 | Vanguard Capital Management LLC | 2.87% | 1.82M | $3.50M |
| 10 | Eversept Partners, LP | 2.40% | 1.52M | $2.92M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for EQ
Equillium Stock Price Forecast. Should You Buy EQ? - StockInvest.us
<a href="https://news.google.com/rss/articles/CBMiRkFVX3lxTFBrWm9oaEh6cjd0Z01MQWd4M1poeWdnWDc3ZE5sZXZ2cHNscUNtTEozcnFhTjlHRjVycExkVWVyRmxPb3gyT2c?oc=5" target="_blank">Equillium Stock Price Forecast. Should You Buy EQ?</a> <font …
EQ | Equillium, Inc. Common Stock Financials - Revenue Breakdown - Quiver Quantitative
<a href="https://news.google.com/rss/articles/CBMidEFVX3lxTE50Mmlsd295czRLbmUwQW95SV9RQnVmaVVhV25fQkhkajVjVlpkYno3WHZlWURDWC13T0RJQUQwd3pUQTFHWUdhY3hSVWJFc01XWDd5UExZZWxld1kzajRic2hBRmhBZ1VFQ2FwUERmcW5iRVFB?oc=5" target="_blank">EQ | Equill…
Here’s What Roth Capital Thinks of Equillium (EQ) Stock - finance.yahoo.com
<a href="https://news.google.com/rss/articles/CBMingFBVV95cUxPMDZBYVB4RGZueXRZT0UtVkczelY2UVMyT2NsSnQwN1JGenBuYXFPRkV1OTIxR0FMdklKV21zeWcxMFJFYkJHVGZKeFhuUEk0Qnk5c3dVeGlEYWxaUDFESXJrTWVUUFRQVUR1N0M3X1AydzJ5TnpETlQ4Rnl6S0hVX1dUZUhKUDFtUnpnZ3…
EQ Forecast — Price Target — Prediction for 2027 - tradingview.com
<a href="https://news.google.com/rss/articles/CBMid0FVX3lxTE1qWlNsM1c3VXhVaWJHT01POFZZLXVMYVp6aFcwSklfeHdQYWJrTFVJa1A4c0FnbnR4Skl2RkhIR19tYm1DWWtteUU3SkwwSlVYMlNRWXR0OFktejBoNHdLSnVaN2djU3Q2UHJUODNBSUhNeTEyVTZR?oc=5" target="_blank">EQ Fore…
EQ - Finviz
<a href="https://news.google.com/rss/articles/CBMiQ0FVX3lxTE81bUtyNXNPNDBncEc0NDF0VWs1MnB4NTRQZ0YzcEdLUkw0TGJ4M3JraXl5TmFJVUZnWTFCdTZERnBFNVU?oc=5" target="_blank">EQ</a> <font color="#6f6f6f">Finviz</font>…
7 Best International Stock Funds to Buy for 2026 | Investing - US News Money
<a href="https://news.google.com/rss/articles/CBMilgFBVV95cUxQNjE5aXBRVmFqb09sdHFIRV90LV9wQWl0bDFsY1JmNFVGUnpiM1lDejA3QllJeUk4V3BIZnE0Ry1yUnJFWkFqcDB3UkJxS0w5bmp0dWhRd0FMeTBIWklZMVBsWjdFSXR6Z0dHaWZBQzJuU2hsZzZSQ3FMdFRVbHZPMldFbGRMc2VSWWY4Vy…
EQ — Frequently Asked Questions
What is the current share price of Equillium, Inc. (EQ)?
As of 2026-09-19 21:16 PDT, Equillium, Inc. (EQ) trades at $2.41 on NasdaqCM. Its 52-week range is $0.84 to $3.20.
What is the market capitalisation of EQ?
Equillium, Inc. (EQ) has a market capitalisation of $152.81M on NasdaqCM.
What is the P/E ratio of EQ?
EQ trades at a trailing price-to-earnings (P/E) ratio of -26.78. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is 2.90.
What is the return on equity (ROE) of EQ?
EQ has a return on equity (ROE) of -58.98%. Its return on capital employed (ROCE) is -81.63%.
Is EQ a good stock to buy?
This page provides a data-driven analysis of Equillium, Inc. (EQ), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.